Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer

References 26

1. 1.

   Ansfield F. J., Kallas G. J., Singson J. P. Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol. 1983;1(2):107-110.

   Not in our library10.1200/jco.1983.1.2.107 (opens in a new tab)

2. 2.

   Blum J. L., Jones S. E., Buzdar A. U., LoRusso P. M., Kuter I., Vogel C., Osterwalder B., Burger H. U., Brown C. S., Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-493.

   Not in our library10.1200/jco.1999.17.2.485 (opens in a new tab)

3. 3.

   Giller S. A., Zhuk R. A., Lidak M. Iu. Analogi pirimidinnukleozidov. I. N1-(alpha-furanidil'nye)-proizvodnye prirodnykh pirimidinovykh osvanii i ikh antimetabolitov. Dokl Akad Nauk SSSR. 1967;176(2):332-335.

   Not in our library

4. 4.

   Hara Y. [5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]. Gan To Kagaku Ryoho. 1984;11(10):2133-2143.

   Not in our library

5. 5.

   Harris B. E., Song R., Soong S. J., Diasio R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990;50(1):197-201.

   Not in our library

6. 6.

   Heggie G. D., Sommadossi J. P., Cross D. S., Huster W. J., Diasio R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47(8):2203-2206.

   Not in our library

7. 7.

   Hirata K., Horikoshi N., Aiba K., Okazaki M., Denno R., Sasaki K., Nakano Y., Ishizuka H., Yamada Y., Uno S. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 1999;5(8):2000-2005.

   Not in our library

8. 8.

   Ichinose Y., Takanashi N., Yano T., Asoh H., Yokoyama H., Tayama K., Hara N., Ohta M. A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer. Cancer. 1995;75(11):2677-2680.

   Not in our library10.1002/1097-0142(19950601)75:11<2677::aid-cncr2820751106>3.0.co;2-d (opens in a new tab)

9. 9.

   Ikenaka K., Shirasaka T., Kitano S., Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gan. 1979;70(3):353-359.

   Not in our library

10. 10.

    Keicho N., Saijo N., Shinkai T., Eguchi K., Sasaki Y., Tamura T., Sakurai M., Sano T., Hoshi A. Phase II study of UFT in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol. 1986;16(2):143-146.

    Not in our library10.1093/oxfordjournals.jjco.a039130 (opens in a new tab)

11. 11.

    Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989;7(4):425-432.

    Not in our library10.1200/jco.1989.7.4.425 (opens in a new tab)

12. 12.

    Moynihan T., Hansen R., Anderson T., Quebbeman E., Beatty P., Ausman R., Ritch P., Chitambar C., Vukelich M. Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol. 1988;11(4):461-464.

    Not in our library10.1097/00000421-198808000-00010 (opens in a new tab)

13. 13.

    Nakai Y., Furuse K., Ohta M., Yamaguchi Y., Fujii M., Asakawa M., Fukuoka M., Yoshida K., Niitani H. Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study. Acta Oncol. 1994;33(5):523-526.

    Not in our library10.3109/02841869409083929 (opens in a new tab)

14. 14.

    Niitani H., Kimura K., Saito T., Nakao I., Abe O., Urushizaki I., Ohta K., Yoshida Y., Kimura T., Kurihara M. [Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study]. Gan To Kagaku Ryoho. 1985;12(10):2044-2051.

    Not in our library

15. 15.

    Ota K., Taguchi T., Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol. 1988;22(4):333-338.

    Not in our library

16. 16.

    Richards F., Perry D. J., Goutsou M., Modeas C., Muchmore E., Rege V., Chahinian A. P., Hirsh V., Poiesz B., Green M. R. Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B. Cancer. 1991;67(12):2974-2979.

    Not in our library10.1002/1097-0142(19910615)67:12<2974::aid-cncr2820671206>3.0.co;2-x (opens in a new tab)

17. 17.

    Seifert P., Baker L. H., Reed M. L., Vaitkevicius V. K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975;36(1):123-128.

    Not in our library10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c (opens in a new tab)

18. 18.

    Shirasaka T., Nakano K., Takechi T., Satake H., Uchida J., Fujioka A., Saito H., Okabe H., Oyama K., Takeda S. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56(11):2602-2606.

    Not in our library

19. 19.

    Shirasaka T., Shimamato Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7(5):548-557.

    Not in our library10.1097/00001813-199607000-00010 (opens in a new tab)

20. 20.

    Shirasaka T., Shimamoto Y., Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53(17):4004-4009.

    Not in our library

21. 21.

    Taguchi T., Inuyama Y., Kanamaru R., Hasegawa K., Akazawa S., Niitani H., Furue H., Kurihara M., Ota K., Suga S. [Phase I study of S-1. S-1 Study Group]. Gan To Kagaku Ryoho. 1997;24(15):2253-2264.

    Not in our library

22. 22.

    Tatsumi K., Fukushima M., Shirasaka T., Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res. 1987;78(7):748-755.

    Not in our library

23. 23.

    Unemi N., Harima K., Daidai Y., Fujihara H., Fujii S. [Experimental studies on antineoplastic action of N 1 -(2'-tetrahydrofuryl)-5-fluorouracil (FT-207)--effect on experimental tumors]. Gan No Rinsho. 1971;17(10):731-742.

    Not in our library

24. 24.

    Van Cutsem E., Findlay M., Osterwalder B., Kocha W., Dalley D., Pazdur R., Cassidy J., Dirix L., Twelves C., Allman D. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18(6):1337-1345.

    Not in our library10.1200/jco.2000.18.6.1337 (opens in a new tab)

25. 25.

    Vogelzang N. J. Continuous infusion chemotherapy: a critical review. J Clin Oncol. 1984;2(11):1289-1304.

    Not in our library10.1200/jco.1984.2.11.1289 (opens in a new tab)

26. 26.

    Weiden P. L., Einstein A. B., Rudolph R. H. Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer. Cancer Treat Rep. 1985;69(11):1253-1255.

    Not in our library

Cited by papers we hold 1

• Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer · 2003
  No notice

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.